MOUNJARO® 7.5mg KwikPen delivers tirzepatide — its active substance — at 7.5mg per 0.6mL dose via a pre-filled KwikPen autoinjector with four once-weekly subcutaneous doses. A dual GIP and GLP-1 receptor agonist developed by Eli Lilly and Company, the 7.5mg strength occupies the intermediate titration step between 5mg and 10mg, supporting progressive dose escalation for adults with type 2 diabetes or chronic weight management patients who have tolerated the 5mg dose and require further clinical response. Licensed professionals seeking to buy MOUNJARO® 7.5mg KwikPen online are encouraged to reach out to the Medical Spa Rx professional support team for ordering guidance.
Product Specifications
- Active Substance: Tirzepatide
- Regulatory Status: FDA-approved prescription pharmaceutical (Initial U.S. Approval: May 2022)
- Molecular Type: Dual GIP/GLP-1 receptor agonist peptide
- Strength: 7.5mg per dose (0.6mL per dose; 30mg/2.4mL per pen)
- Dosage Form: Solution for injection, single-patient-use pre-filled KwikPen with 4 doses
- Manufacturer: Eli Lilly and Company Limited
- Storage Requirements: Refrigerate at 2°C to 8°C; do not freeze; protect from light; may be stored unrefrigerated at up to 30°C for up to 30 days
- Intended Use: Adults with type 2 diabetes; chronic weight management
- Pack Sizes: 1 pre-filled KwikPen (4 doses); confirm additional pack sizes with your pharmacist or nurse
- Package Dimensions: Width: 60mm / Height: 40mm / Length: 150mm / Weight: 60g
Regulatory status current as of June 2026. Licensed practitioners should verify applicable local requirements before prescribing or supplying.
What Is MOUNJARO® 7.5mg KwikPen?
Tirzepatide is the active substance (INN) in MOUNJARO®, Eli Lilly’s proprietary brand name. Tirzepatide is the international non-proprietary name applied by regulatory bodies. The active substance, formulation, and mechanism of action are consistent regardless of which name appears on documentation or clinical correspondence.
The 7.5mg dose sits between the 5mg and 10mg steps in the approved titration schedule. It is appropriate for adults with type 2 diabetes or weight-management patients who have completed at least 4 weeks on the 5mg dose and whose doctor or pharmacist has confirmed the need for further blood sugar control or weight-management response. Each pre-filled KwikPen contains 2.4mL of tirzepatide solution and delivers four doses of 7.5mg at 0.6mL each, administered once weekly by subcutaneous injection [5]. Standard pack sizes comprise one KwikPen per pack; practitioners should confirm available pack sizes at each dispensing point.
Licensed professionals can buy MOUNJARO® by contacting the Medical Spa Rx professional support team for sourcing guidance.
Mechanism of Action
Tirzepatide is a first-in-class dual incretin receptor agonist, simultaneously activating glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors through distinct binding domains on a single engineered peptide. Engaging both incretin pathways produces broader and more complementary metabolic effects than GLP-1 receptor agonism alone [3].
The two receptor pathways contribute distinct but reinforcing actions:
- GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion, suppresses glucagon release during hyperglycemia, delays gastric emptying, and promotes satiety. Together, they reduce both fasting and postprandial blood sugar levels and support reductions in energy intake.
- GIP receptor activation: Further potentiates insulin secretion and modulates adipose lipid storage. Clinical evidence also suggests that GIP activity contributes to the improved gastrointestinal tolerability profile observed with tirzepatide relative to GLP-1 monotherapy [1].
Because both pathways drive insulin release in a glucose-dependent manner, the standalone hypoglycemia risk with tirzepatide monotherapy is low — a clinically meaningful differentiator when managing adults with type 2 diabetes on complex medication regimens [1]. In the SURPASS phase III program, tirzepatide demonstrated clinically meaningful, dose-dependent reductions in HbA1c and body weight compared with placebo and active comparators [1], and produced greater reductions in both measures than semaglutide once weekly in a direct head-to-head comparison [2].
The risk of low blood sugar increases when tirzepatide is used alongside insulin or sulfonylureas, and dose adjustments to those agents may be required. A doctor or pharmacist should review the full prescribing information before initiating or adjusting treatment [3].
Indications and Patient Criteria
MOUNJARO® 7.5mg KwikPen is indicated for adults who require additional glycaemic control or chronic weight management following tolerability of the 5mg dose. Dose escalation to 7.5mg should be individualized according to clinical response, glycaemic targets, and gastrointestinal tolerability [3].
Approved indications include:
- Type 2 diabetes: As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Not indicated for type 1 diabetes or diabetic ketoacidosis [3].
- Chronic weight management: For adults with a BMI of 30kg/m² or greater, or 27kg/m² or greater with at least one weight-related comorbidity, including obstructive sleep apnoea where applicable in the relevant jurisdiction [3]
Before escalating to the 7.5mg dose, clinicians should evaluate:
- Renal function and the risk of kidney injury secondary to GI dehydration
- Concomitant medications, particularly insulin and sulfonylureas, where hypoglycemia risk may require partner-agent dose adjustment
- Cardiovascular history and any relevant comorbidities
- The patient’s overall clinical profile and tolerability of the preceding dose
MOUNJARO® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and in those with known hypersensitivity to tirzepatide or any excipient in the formulation [3].
Administration and Injection Technique
MOUNJARO® 7.5mg KwikPen is administered as a once-weekly subcutaneous injection, at any time of day with or without meals, on the same preferred day each week [3]. Approved injection sites are the abdomen, thigh, or outer upper arm. Sites must be rotated with each weekly administration; patients should avoid bruised, scarred, or inflamed areas, and persistent injection site reactions require clinical review.
General Injection Technique Steps
- Remove the pre-filled pen cap and visually inspect the solution — it should appear clear, colorless to slightly yellow, and free of particles.
- Clean the selected injection site using standard aseptic practice.
- Position the pen perpendicular to the skin, press the activation button, and hold for 10 seconds.
- Confirm the dose window shows complete depletion before withdrawing the needle.
- Dispose of the used pen in an approved sharps container.
A pharmacist or nurse should counsel patients on correct pre-filled pen technique and disposal, particularly when transitioning between dose strengths or pack sizes [5].
For patients also receiving insulin, MOUNJARO® must not be co-administered at the same injection site, though adjacent body regions may be used with appropriate spacing. Blood sugar levels monitoring is especially important in this group, and partner-agent dose adjustment may be necessary [3].
Because tirzepatide delays gastric emptying, it may alter the absorption of oral medications — practitioners should assess all instances where tirzepatide could interact with other medicines currently prescribed [3]. If a dose is missed and four days or fewer have elapsed, administer as soon as practicable and continue the regular schedule. If more than four days have passed, skip the missed dose and resume the usual weekly schedule. Doses must never be doubled. Patients experiencing recurring schedule interruptions should be advised to talk to their doctor [3].
Healthcare professionals sourcing treatments for clinical programs can buy weight loss treatments by contacting the Medical Spa Rx professional support team for guidance on available options.
Side Effects and Safety Profile
The safety profile of MOUNJARO® 7.5mg is consistent with the dual incretin class. Adverse reactions are predominantly gastrointestinal, occur most commonly during dose initiation or escalation, and typically improve as patients adapt to each dose level [1].
Common adverse reactions include:
- Nausea, vomiting, and diarrhea
- Constipation and decreased appetite
- Abdominal pain and dyspepsia
These reactions are generally mild to moderate in severity. Patients should be counseled to anticipate GI symptoms in the early weeks of treatment and advised on management strategies such as smaller meal sizes and lower-fat dietary choices.
Rare but serious adverse events include:
- Acute pancreatitis — discontinue MOUNJARO® if suspected and do not restart following a confirmed diagnosis
- Gallbladder disease, including cholelithiasis and biliary events
- Acute kidney injury, most often secondary to dehydration from severe GI events — patients should maintain adequate hydration and seek prompt medical attention if GI symptoms become severe
- Hypersensitivity reactions, including urticaria and anaphylaxis — discontinue immediately and do not readminister
Because insulin secretion remains glucose-dependent, the standalone risk of hypoglycemia with tirzepatide is low [1]. However, co-prescription of insulin or sulfonylureas substantially increases this risk, and blood sugar level monitoring with appropriate dose adjustments to the partner agent is essential [3].
Practitioners should also consider the effect of delayed gastric emptying on the absorption timing of oral medications, particularly during treatment initiation or dose escalation. Patients should talk to their doctor and report adverse events through the applicable pharmacovigilance system in their jurisdiction [3].
Legal Status of MOUNJARO® 7.5mg KwikPen
MOUNJARO® (tirzepatide) is an FDA-approved prescription-only medicine, manufactured by Eli Lilly and Company Limited [3]. In the European Union, marketing authorization has been granted by the European Medicines Agency for its approved indications [4]. Supply is restricted to licensed medical professionals and registered healthcare settings across all jurisdictions.
When buying online, licensed practitioners should confirm that MOUNJARO® is approved and appropriately regulated in their target market, and that supply is obtained through authorized pharmaceutical distributors. Practitioners can check for wholesale buying options by contacting the Medical Spa Rx professional support team for current guidance on supply arrangements. Those considering buying MOUNJARO® KwikPen wholesale should ensure all applicable cold-chain, storage, and regulatory requirements are met. A doctor or pharmacist should verify current approved indications and jurisdiction-specific prescribing conditions before ordering or administering this product [3].Regulatory status current as of June 2026.
References
- Rosenstock J, Vázquez L, Del Prato S, et al. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials. Diabetes Care. 2023. https://pubmed.ncbi.nlm.nih.gov/37673061/
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use: Prescribing Information. U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
- European Medicines Agency. Mounjaro: INN: tirzepatide — Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
- Eli Lilly and Company. Mounjaro® (tirzepatide injection) KwikPen® FAQs / Instructions for Use. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen
The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.